tacrolimus and omeprazole. The revenue was driven by global generics segment — Rs.2,128 crore (Rs.1,358 crore) with a growth of 57 per cent, led by the North American market. The pharmaceutical services and active ingredients contributed Rs.556 crore (Rs.
